EMILY NANCE: Open Payments
NPI 1073254439 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,511 in 133 payments from 30 companies in 2025. Trend: 2023 $1,447 · 2024 $2,812 · 2025 $2,511
Food & beverage: $2,499Education: $12
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $539 |
| AstraZeneca Pharmaceuticals LP | 13 | $340 |
| Novo Nordisk Inc | 10 | $190 |
| Lilly USA, LLC | 10 | $175 |
| PFIZER INC. | 11 | $160 |
| Lundbeck LLC | 7 | $136 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $79 |
| Viatris Specialty LLC | 4 | $70 |
Products named: VRAYLAR, REXULTI, FARXIGA, QULIPTA, UBRELVY, Ozempic, MOUNJARO, CAPLYTA.
Industry payments across IA — which companies pay providers there.
